GB0922209D0 - Proteins, nucleic acid molecules and compositions - Google Patents

Proteins, nucleic acid molecules and compositions

Info

Publication number
GB0922209D0
GB0922209D0 GBGB0922209.2A GB0922209A GB0922209D0 GB 0922209 D0 GB0922209 D0 GB 0922209D0 GB 0922209 A GB0922209 A GB 0922209A GB 0922209 D0 GB0922209 D0 GB 0922209D0
Authority
GB
United Kingdom
Prior art keywords
proteins
compositions
nucleic acid
acid molecules
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0922209.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham filed Critical University of Nottingham
Priority to GBGB0922209.2A priority Critical patent/GB0922209D0/en
Publication of GB0922209D0 publication Critical patent/GB0922209D0/en
Priority to PCT/GB2010/052158 priority patent/WO2011073692A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
GBGB0922209.2A 2009-12-18 2009-12-18 Proteins, nucleic acid molecules and compositions Ceased GB0922209D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0922209.2A GB0922209D0 (en) 2009-12-18 2009-12-18 Proteins, nucleic acid molecules and compositions
PCT/GB2010/052158 WO2011073692A1 (en) 2009-12-18 2010-12-20 Proteins, nucleic acid molecules and compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0922209.2A GB0922209D0 (en) 2009-12-18 2009-12-18 Proteins, nucleic acid molecules and compositions

Publications (1)

Publication Number Publication Date
GB0922209D0 true GB0922209D0 (en) 2010-02-03

Family

ID=41717232

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0922209.2A Ceased GB0922209D0 (en) 2009-12-18 2009-12-18 Proteins, nucleic acid molecules and compositions

Country Status (2)

Country Link
GB (1) GB0922209D0 (en)
WO (1) WO2011073692A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
MX368531B (en) 2010-07-28 2019-10-07 Gliknik Inc Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions.
EP2880057A4 (en) * 2012-08-02 2016-03-23 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
CN110894231A (en) * 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 Immunomodulatory proteins
BR112016020368A2 (en) 2014-03-05 2018-01-23 Ucb Biopharma Sprl multimeric fc proteins
AU2015248785A1 (en) * 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
CN106661125B (en) 2014-05-02 2021-10-01 动量制药公司 Compositions and methods involving engineered Fc constructs
GB201412821D0 (en) * 2014-07-18 2014-09-03 Liverpool School Tropical Medicine Polymeric proteins and uses thereof
US10118951B2 (en) 2014-12-19 2018-11-06 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey
EP3265131A1 (en) * 2015-03-05 2018-01-10 UCB Biopharma SPRL Polymeric fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
MX394116B (en) 2015-07-24 2025-03-19 Gliknik Inc FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERED MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING.
GB201515745D0 (en) * 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
US10865232B2 (en) * 2015-11-13 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-IG fusion protein for cancer immunotherapy
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
KR102635635B1 (en) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 Compositions and methods related to engineered fc constructs
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
CN110650748B (en) 2017-01-06 2024-01-02 动量制药公司 Compositions and methods related to engineered Fc constructs
CN113271972B (en) 2018-11-14 2025-06-17 Jn生物科学有限责任公司 Multimeric hybrid Fc protein for replacing IVIG
CN109942719A (en) * 2019-05-07 2019-06-28 中国人民解放军陆军军医大学第二附属医院 A kind of Staphylococcus aureus fusion protein and its protein expression vector and purification method
CN115210264A (en) * 2020-02-27 2022-10-18 华辉安健（北京）生物科技有限公司 Soluble ACE2 and fusion proteins, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (en) 1982-08-30 1984-03-02 Musashi Eng Kk Paper leaf discriminating method
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6114515A (en) * 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4

Also Published As

Publication number Publication date
WO2011073692A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
EP2585595B8 (en) Rna molecules and uses thereof
SG2014014617A (en) Nucleic acid analysis
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
PL2406399T3 (en) Mirac proteins
IL214643A0 (en) Specific binding proteins and uses thereof
GB2489187B (en) Compositions, methods and related uses for cleaving modified DNA
BRPI0922957A2 (en) nucleic acid vector modification
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
EP2415869A4 (en) Modified oligo-nucleic acid molecule, preparation method and uses thereof
GB0812862D0 (en) Nucleic acid amplification
EP2658988A4 (en) Nucleic acid sample preparation methods and compositions
GB2466379B (en) Protein stabilizer
GB0816976D0 (en) Protein
IL240134A0 (en) Novel proteins
IL205237A0 (en) Nucleic acid complex and nucleic acid delivery composition
ZA201303254B (en) Small viral rna molecules and uses thereof
EP2405001A4 (en) Nucleic acid complex and nucleic acid-delivering composition
GB0903562D0 (en) RNA molecules
GB0916378D0 (en) Proteins, nucleic acid molecules and compositions
GB0906906D0 (en) Nucleic acid molecule
GB0818627D0 (en) Protein
AU2009901920A0 (en) Nucleic acid molecules and uses therefor
AU2009904482A0 (en) Nucleic Acid Molecule
AU2009905381A0 (en) Nucleic Acid Molecule

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)